No fee unless we recover compensation for your family Text size 833-4-ASBESTOS (833-427-2378) Free Case Review

Study

Breakthrough in Treatment of Asbestos Cancer?

Update, November 2026: further analyses of the NERO trial were presented at the European Society for Medical Oncology congress in October 2025. We found no full journal report of the trial yet, and niraparib is still being studied for mesothelioma.

A UK trial found that a PARP inhibitor, niraparib, slowed the worsening of mesothelioma that had come back after chemotherapy.

For decades, mesothelioma, a cancer almost always tied to asbestos, has been one of the most feared diagnoses linked to asbestos exposure. Treatment options are few, especially once the cancer comes back after first treatment. In April 2025, researchers in the UK reported a clinical trial showing that a drug called niraparib delayed the cancer's progress in these patients. Niraparib belongs to a class of drugs called PARP inhibitors, which are already standard treatment for some breast, ovarian and prostate cancers with certain gene changes.

The Silent Danger of Asbestos

Asbestos isn't just a problem of the past. Its use peaked in the 20th century, but the disease it causes is still showing up today. Prized for heat resistance and durability, asbestos was added to insulation, ceiling tiles, brake pads, cement and many other products. All types of asbestos can cause disease, including asbestosis, pleural plaques, lung, laryngeal and ovarian cancer, and mesothelioma, a cancer that develops in the lining of the lungs, abdomen or heart.

Latency: Asbestos cancers like mesothelioma can take 20 to 50 years or more to appear.

Mesothelioma commonly takes 20 to 50 years or more to develop after exposure. This is why people who worked with asbestos decades ago, such as construction workers, mechanics and veterans, are being diagnosed now. Many don't realize they were exposed until they are diagnosed.

What Makes Mesothelioma So Difficult to Treat

Mesothelioma is hard to treat. It is often found late, and in the chest it tends to spread along the lining of the lung rather than forming a single lump that is easy to remove. Asbestos fibers that lodge in the body are hard to clear and can cause long-term inflammation that contributes to cancer.

Standard treatments can ease symptoms and slow the disease, but long-term survival is uncommon. Only around 5% of people diagnosed with mesothelioma survive five years or more, according to the trial's lead researcher. When the cancer comes back after first treatment, there are very few further options.

What Are PARP Inhibitors?

PARP inhibitors are targeted cancer drugs that block a protein called PARP (poly ADP-ribose polymerase), which helps cells repair breaks in one strand of their DNA.

Turning a cancer's weakness against it

Some cancer cells have lost other DNA repair tools, often because of changes in genes such as BRCA1 and BRCA2, which fix breaks in both strands of DNA. Those cells depend more on PARP. When PARP is blocked, they cannot repair the damage and die. Scientists call this "synthetic lethality."

Studies of mesothelioma tumors have found changes in DNA repair genes in many patients. An earlier small UK trial, MiST1, tested a different PARP inhibitor (rucaparib) in mesothelioma with BAP1 or BRCA1 loss and met its goal. That laid the groundwork for a randomized trial.

Inside the NERO Trial

The NERO trial, run by researchers at the University of Leicester and the Cancer Research UK Southampton Clinical Trials Unit, sponsored by University Hospital Southampton and funded by the charity Asthma + Lung UK, tested whether niraparib could help people whose mesothelioma had grown after platinum chemotherapy. It enrolled 88 patients at 11 UK hospitals. Patients with any type of mesothelioma (pleural or peritoneal) could take part.

Patients were assigned at random, two to one, to niraparib plus active symptom control or to active symptom control alone. The main goal was to see whether the drug delayed the cancer getting worse.

The results were presented at the American Association for Cancer Research meeting in April 2025. Patients who took niraparib went, on average, about 1.5 months longer before their cancer got worse, and the drug reduced the risk of the cancer worsening or death by 27%. That is a modest gain, but some patients have done much better. James Fox, an 83-year-old architect who worked on building sites where asbestos was common, was diagnosed in early 2018 and given months to live. After surgery, chemotherapy and immunotherapy stopped working, he joined NERO, responded well, and was still taking the drug when the results were announced.

Why This Matters

Researchers said this was the first time this kind of drug had been shown to improve progression-free survival for mesothelioma patients. It is a phase II trial, so it is a step toward, not proof of, a new standard treatment.

Researchers still don't fully understand why the drug works better in some patients than others. They are studying features of each tumor, including immune signals and gene changes, to find who is most likely to benefit. In later analyses presented in October 2025, an artificial-intelligence tool found that how varied the cells within a tumor were helped predict who benefited.

The Ongoing Legacy of Asbestos

Asbestos is banned or restricted in many countries, but because of the long delay before disease appears, people are still being diagnosed with mesothelioma. In the U.S., those at risk include construction and textile workers, auto mechanics, veterans, shipyard workers and others who worked with asbestos, along with family members exposed to dust brought home on work clothes. Many were exposed without being told of the risk, even after asbestos makers knew it caused disease. See our pages on occupations with asbestos exposure.

Asbestos also remains in many older homes, schools and public buildings. Left undisturbed and in good condition, it is generally not a hazard, but renovation and demolition can release fibers, so that work should be done by licensed professionals.

The Cost of Treatment and Asbestos Trusts

A cancer diagnosis affects the whole family. Even with insurance, the cost of treatment, travel and lost wages can be overwhelming.

There is financial help for many families. Many companies that made asbestos products went bankrupt after a wave of lawsuits, and the bankruptcy courts set up asbestos trusts to pay people they harmed. Many of these trusts are still paying claims.

A trust claim does not require a court case. For mesothelioma patients, that can mean payment sooner than a lawsuit. Many people with mesothelioma file both trust claims and a lawsuit against companies that are still in business.

What's Next?

The NERO results are an important step, but not the final answer. Researchers are working out why some patients respond better than others, so the drug can be offered to those most likely to benefit.

For patients and families facing mesothelioma that has come back, this trial offers some new hope. It is not a cure, but in a disease with few options, it is a step forward. Patients who are interested in trials of new treatments should ask their cancer doctor.

Our take

What this means if you have, or may have, an asbestos claim

This trial doesn't change who can bring a claim or what a claim is worth, but it is a reason for patients whose mesothelioma has come back to ask their doctor about clinical trials. A claim can also help pay for treatment and travel to a specialist center. Most people with mesothelioma were exposed to asbestos decades ago at work or at home, and several trusts and companies may share responsibility. Our mesothelioma page explains treatment options and how claims work.

Read something that sounds familiar? Free case review. No records or product names needed, and no fee unless we recover compensation for your family.

Call 833-4-ASBESTOS Request a review
Sources

This post is news and commentary, provided for general information. It is not legal advice and does not create an attorney-client relationship.